Ribomic Inc.
Tokyo Stock Exchange 4591.T
Ribomic Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2024
Ribomic Inc. Return on Capital Employed (ROCE) is NA for the year ending March 31, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
-
Ribomic Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2021 was -20.67%, a 50.68% change year over year.
-
Ribomic Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2020 was -41.91%.
Key data
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Market news
Loading...
Don’t Miss A Beat
Tokyo Stock Exchange: 4591.T
| CEO | Mr. Yoshikazu Nakamura Ph.D. |
| IPO Date | Sept. 25, 2014 |
| Location | Japan |
| Headquarters | Shirokanedai Usui Building |
| Employees | 24 |
| Sector | Health Care |
| Industries | |
Description
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Key trends
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email